A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Clinical trial NCT06624670 · RECRUITING

Trial details

NCT number: NCT06624670
Sponsor: LEO Pharma
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Pyoderma Gangrenosum

Start date: 2025-02-05
Primary completion: 2027-11-12
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.